t
| Date | 22 Nov 2021 |
| Time | 11:00:03 |
| Category | Director/PDMR dealings |
| ID | 1308T |
22 November 2021
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Vulpes Life Sciences Fund and Testudo Fund, which are controlled by Non-Executive Director, Stephen Diggle, have purchased 98,533 Ordinary Shares of 1 pence each ("shares") and 99,471 shares respectively, at an aggregate price of 41.9p per share.
Following this transaction, Vulpes Life Sciences Fund is interested in 13,909,203 shares, representing 13.86% of the Company's current issued share capital and Vulpes Testudo Fund is interested in 1,031,675 shares, representing 1.03% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in 14,940,878 shares, representing approximately 14.89% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a) |
Name |
Stephen Diggle |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Non-Executive Director |
||||||
|
b) |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Oxford BioDynamics Plc |
||||||
|
b) |
LEI |
2138005Y1TK258O5U928 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 |
||||||
|
b) |
Nature of the transaction |
Acquisition of ordinary shares |
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information - Aggregated volume - Price
|
|
||||||
|
e) |
Dates of the transactions |
18 & 19 November 2021 |
||||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||||
For further details please contact:
|
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
|
+44 (0)1865 518910 |
|
Shore Capital Nominated Adviser and Broker Stephane Auton John More
|
+44 (0)20 7408 4090 |
|
Instinctif Partners |
Tel: +44 (0)20 7457 2020 |
|
Melanie Toyne-Sewell / Nathan Billis |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. Its next product will be EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.